Cancer Cell Line Screening (CCP-58)

AddexBio offers Cancer Cell Line Screening of over 150 Cancer Cell Lines Table. Cell lines are of human origin and are well characterized. You can also select cancer cells from our cancer cell-58 panel (CCP-58) that is similar to those included in the NCI-60 Panel of cancer cell lines or clients are welcome to design a special panel of cells that is most relevant to their specific research need. We will assist you with the selection of cell lines by tissue of origin or for the presence of specific gene mutations responsible for cancer induction or responsible for drug resistance.

CCP-58 panel

The CCP-58 panel is a set of 58 representative human cancer cell lines derived from diverse tissues; brain, blood and bone marrow, breast, colon, kidney, lung, ovary, prostate and skin. Researchers across the world have employed these cell lines to characterize drug effectiveness.

Flexibility

AddexBio has adopted a very flexible, screening approach with multiple end point parameters available including proliferation or other assays (e.g. ion channels) in the medium conditions of interest.

• 96-well screening plate format
• 3 to 4 weeks data turnaround time
• Choice of proliferation assay method (Alamar blue, CyQuant, XTT, MTS)

Service and price structure of our CCP-58 panel screening

1-5 cell lines	$700/line 	6 compounds/concentration/time-point   2 controls, or
  			        1 compound at 6 concentrations/time-point 2 controls
15 cell lines	$6,100
30 cell lines	$12,000

Related References to Cancer Cell Line Screening:

1. Ko D, Xu W, and Windle B. Gene function classification using NCI-60 cell line gene expression profiles. Comput Biol Chem 29: 412-419, 2005.
2. Li L, Zhou X, Ching WK, and Wang P. Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines. BMC Bioinformatics 11: 501.
3. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, and Weinstein JN. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 8: 713-724, 2009.
4. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Espina V, Munson PJ, Petricoin E, 3rd, Liotta LA, and Weinstein JN. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100: 14229-14234, 2003.
5. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, and Gottesman MM. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7: 3081-3091, 2008.
6. Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, Parchment R, Doroshow J, Weinstein JN, and Pommier Y. Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 70: 2191-2203.
7. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, and Kirsch IR. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63: 8634-8647, 2003.
8. Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, Pommier Y, and Weinstein JN. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 10: 277, 2009.
9. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, and Issa JP. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 67: 11335-11343, 2007.
10. Sokilde R, Kaczkowski B, Podolska A, Cirera S, Gorodkin J, Moller S, and Litman T. Global microRNA analysis of the NCI-60 cancer cell panel. Mol Cancer Ther 10: 375-384.
11. Wallqvist A, Huang R, and Covell DG. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors. J Chem Inf Model 47: 1414-1427, 2007.
12. Weinstein JN. Integromic analysis of the NCI-60 cancer cell lines. Breast Dis 19: 11-22, 2004.

Please contact us directly for more information or to obtain a quotation for your specific studies.

Table is our current in-house list of cell lines available for screening.

The CCP-58 panel comprises the following tumor cell lines:

* MDA-MB-435 and SNB19 are known misidentified or contaminated cells and are not included in our CCP-58 panel, please refer to Resources